Cybin (HELP) Cash from Financing Activities (2020 - 2026)
Cybin's (HELP) quarterly Cash from Financing Activities came in at -$169000.0 in Q1 2026, down 101.16% YoY from $14.6 million in Q1 2025, and down 100.12% on a QoQ basis from $143.7 million in Q4 2025.
Cybin (HELP) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Cybin (HELP) has 7 years of Cash from Financing Activities data on file, last reported at -$169000.0 in Q1 2026.
- Quarterly Cash from Financing Activities fell 101.16% year-over-year to -$169000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $198.2 million (up 1310.85% YoY) and the FY2026 annual result came in at $198.2 million, up 1306.45% from the prior year.
- Cash from Financing Activities fell to -$169000.0 in Q1 2026, from $143.7 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $143.7 million in Q4 2025 to a low of -$271000.0 in Q3 2024.
- A 5-year average of $27.1 million and a median of $2.6 million in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities slumped 106.56% — and 2025, when it surged 112403.12%.
- Tracing HELP's Cash from Financing Activities over 5 years: stood at $2.5 million in 2022, then soared by 1045.56% to $29.2 million in 2023, then tumbled by 100.44% to -$128000.0 in 2024, then surged by 112403.12% to $143.7 million in 2025, then slumped by 100.12% to -$169000.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$169000.0 (Q1 2026), $143.7 million (Q4 2025), and $27000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Cybin | 417.29 Mn | 417.29 Mn | - | -169,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -169,000.00 |
| Mar 31, 2026 | -169,000.00 |
| Dec 31, 2025 | 143.75 Mn |
| Dec 31, 2025 | 143.75 Mn |
| Sep 30, 2025 | 27,000.00 |
| Sep 30, 2025 | 27,000.00 |
| Jun 30, 2025 | 54.63 Mn |
| Jun 30, 2025 | 54.63 Mn |
| Mar 31, 2025 | 14.62 Mn |
| Mar 31, 2025 | 14.62 Mn |
| Dec 31, 2024 | -128,000.00 |
| Dec 31, 2024 | -128,000.00 |
| Sep 30, 2024 | -271,000.00 |
| Sep 30, 2024 | -271,000.00 |
| Jun 30, 2024 | -172,000.00 |
| Jun 30, 2024 | -172,000.00 |
| Mar 31, 2024 | 141.64 Mn |
| Mar 31, 2024 | 141.64 Mn |
| Dec 31, 2023 | 29.19 Mn |
| Dec 31, 2023 | 29.19 Mn |